Paul K. Fyfe

Paul K. Fyfe

Auto-generated profile, based on publicly available information

Paul K. Fyfe

Drug Discovery Unit, School of Life Sciences, University of Dundee

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Science Immunology
Verified
Journal Article
Closed access
SGSilvia Gaggero
Silvia Gaggero
JMJonathan Martinez-Fabregas
Jonathan Martinez-Fabregas
ACAdeline Cozzani
Adeline Cozzani
PFPaul K. Fyfe
Paul K. Fyfe
MLMalo Leprohon
Malo Leprohon
SMSuman Mitra
Suman Mitra
Cytokines interact with their receptors in the extracellular space to control immune responses. How the physicochemical properties of the extracellular space influence cytokine signaling is incompletely elucidated. Here, we show that the activity of interleukin-2 (IL-2), a cytokine critical to T cell immunity, is profoundly affected by pH, limiting IL-2 signaling within the acidic environment of tumors. Generation of lactic acid by tumors limits STAT5 activation, effector differentiation, and antitumor immunity by CD8 + T cells and renders high-dose IL-2 therapy poorly effective. Directed evolution enabled selection of a pH-selective IL-2 mutein (Switch-2). Switch-2 binds the IL-2 receptor subunit IL-2Rα with higher affinity, triggers STAT5 activation, and drives CD8 + T cell effector function more potently at acidic pH than at neutral pH. Consequently, high-dose Switch-2 therapy induces potent immune activation and tumor rejection with reduced on-target toxicity in normal tissues. Last, we show that sensitivity to pH is a generalizable property of a diverse range of cytokines with broad relevance to immunity and immunotherapy in healthy and diseased tissues.

15 September 2020 in Science Signaling
Verified
Journal Article
Closed access
CGClaire Gorby
Claire Gorby
JBJunel Sotolongo Bellón
Junel Sotolongo Bellón
SWStephan Wilmes
Stephan Wilmes
WWWalid Warda
Walid Warda
EPElizabeth Pohler
Elizabeth Pohler
IMIgnacio Moraga
Ignacio Moraga
An IL-10 variant with higher affinity for a receptor subunit remains effective at low concentrations.

3 August 2022 in EMBO Reports
Verified
Journal Article
Open access
YJYibo Jin
Yibo Jin
PFPaul K Fyfe
Paul K Fyfe
SGScott Gardner
Scott Gardner
SWStephan Wilmes
Stephan Wilmes
DBDoryen Bubeck
Doryen Bubeck
IMIgnacio Moraga
Ignacio Moraga
Interleukin 27 (IL‐27) is a heterodimeric cytokine that elicits potent immunosuppressive responses. Comprised of EBI3 and p28 subunits, IL‐27 binds GP130 and IL‐27Rα receptor chains to activate the JAK/STAT signaling cascade. However, how these receptors recognize IL‐27 and form a complex capable of phosphorylating JAK proteins remains unclear. Here, we used cryo electron microscopy (cryoEM) and AlphaFold modeling to solve the structure of the IL‐27 receptor recognition complex. Our data show how IL‐27 serves as a bridge connecting IL‐27Rα (domains 1–2) with GP130 (domains 1–3) to initiate signaling. While both receptors contact the p28 component of the heterodimeric cytokine, EBI3 stabilizes the complex by binding a positively charged surface of IL‐27Rα and Domain 1 of GP130. We find that assembly of the IL‐27 receptor recognition complex is distinct from both IL‐12 and IL‐6 cytokine families and provides a mechanistic blueprint for tuning IL‐27 pleiotropic actions.

19 April 2021 in eLife
Verified
Journal Article
Open access
SWStephan Wilmes
Stephan Wilmes
PJPolly Jeffrey
Polly Jeffrey
JMJonathan Martinez-Fabregas
Jonathan Martinez-Fabregas
MHMaximillian Hafer
Maximillian Hafer
PFPaul K Fyfe
Paul K Fyfe
IMIgnacio Moraga
Ignacio Moraga
Cytokines elicit pleiotropic and non-redundant activities despite strong overlap in their usage of receptors, JAKs and STATs molecules. We use IL-6 and IL-27 to ask how two cytokines activating the same signaling pathway have different biological roles. We found that IL-27 induces more sustained STAT1 phosphorylation than IL-6, with the two cytokines inducing comparable levels of STAT3 phosphorylation. Mathematical and statistical modeling of IL-6 and IL-27 signaling identified STAT3 binding to GP130, and STAT1 binding to IL-27Rα, as the main dynamical processes contributing to sustained pSTAT1 levels by IL-27. Mutation of Tyr613 on IL-27Rα decreased IL-27-induced STAT1 phosphorylation by 80% but had limited effect on STAT3 phosphorgylation. Strong receptor/STAT coupling by IL-27 initiated a unique gene expression program, which required sustained STAT1 phosphorylation and IRF1 expression and was enriched in classical Interferon Stimulated Genes. Interestingly, the STAT/receptor coupling exhibited by IL-6/IL-27 was altered in patients with systemic lupus erythematosus (SLE). IL-6/IL-27 induced a more potent STAT1 activation in SLE patients than in healthy controls, which correlated with higher STAT1 expression in these patients. Partial inhibition of JAK activation by sub-saturating doses of Tofacitinib specifically lowered the levels of STAT1 activation by IL-6. Our data show that receptor and STATs concentrations critically contribute to shape cytokine responses and generate functional pleiotropy in health and disease.

7 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGScott Gardner
Scott Gardner
YJYibo Jin
Yibo Jin
PFPaul K. Fyfe
Paul K. Fyfe
TVTomas B. Voisin
Tomas B. Voisin
JBJunel Sotolongo Bellón
Junel Sotolongo Bellón
DBDoryen Bubeck
Doryen Bubeck
IL-11 and IL-6 activate signalling via assembly of the cell surface receptor gp130; however, it is unclear how signals are transmitted across the membrane to instruct cellular responses. Here we solve the cryoEM structure of the IL-11 receptor recognition complex to discover how differences in gp130-binding interfaces may drive signalling outcomes. We explore how mutations in the IL6ST gene encoding for gp130, which cause severe immune deficiencies in humans, impair signalling without blocking cytokine binding. We use cryoEM to solve structures of both IL-11 and IL-6 complexes with a mutant form of gp130 associated with human disease. Together with molecular dynamics simulations, we show that the disease-associated variant led to an increase in flexibility including motion within the cytokine-binding core and increased distance between extracellular domains. However, these distances are minimized as the transmembrane helix exits the membrane, suggesting a stringency in geometry for signalling and dimmer switch mode of action.

21 August 2007 in Biochemistry
Verified
Journal Article
Closed access
PFPaul K. Fyfe
Paul K. Fyfe
JPJane Potter
Jane Potter
JCJade Cheng
Jade Cheng
CWChristopher M. Williams
Christopher M. Williams
AWAshley J. Watson
Ashley J. Watson
MJMichael R. Jones
Michael R. Jones